Invesco
BBIO icon

Invesco’s BridgeBio Pharma BBIO Stock Holding History

Invesco’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$276M Sell
3,700,934
-891,880
-19% -$62.5M 0.02% 619
2026
Q1 		$341M Sell
4,592,814
-238,491
-5% -$17.3M 0.03% 477
2025
Q4 		$370M Buy
4,831,305
+902,648
+23% +$59.3M 0.03% 411
2025
Q3 		$204M Buy
3,928,657
+1,127,592
+40% +$55M 0.03% 658
2025
Q2 		$121M Buy
2,801,065
+594,902
+27% +$21.6M 0.02% 775
2025
Q1 		$76.3M Buy
2,206,163
+1,313,036
+147% +$44.3M 0.01% 876
2024
Q4 		$24.5M Buy
893,127
+35,670
+4% +$922K ﹤0.01% 1385
2024
Q3 		$21.8M Sell
857,457
-231,263
-21% -$6.07M ﹤0.01% 1430
2024
Q2 		$27.6M Buy
1,088,720
+90,095
+9% +$2.46M 0.01% 1277
2024
Q1 		$30.9M Sell
998,625
-273,911
-22% -$9.32M 0.01% 1242
2023
Q4 		$51.4M Buy
1,272,536
+112,383
+10% +$3.38M 0.01% 992
2023
Q3 		$30.6M Buy
1,160,153
+475,684
+69% +$13.5M 0.01% 1157
2023
Q2 		$11.8M Buy
684,469
+631,161
+1,184% +$9.5M ﹤0.01% 1697
2023
Q1 		$884K Buy
53,308
+10,681
+25% +$125K ﹤0.01% 2952
2022
Q4 		$325K Sell
42,627
-276,255
-87% -$2.64M ﹤0.01% 3477
2022
Q3 		$3.17M Buy
318,882
+275,673
+638% +$2.86M ﹤0.01% 2440
2022
Q2 		$392K Sell
43,209
-981
-2% -$8.21K ﹤0.01% 3448
2022
Q1 		$449K Sell
44,190
-3,649
-8% -$37.4K ﹤0.01% 3447
2021
Q4 		$798K Sell
47,839
-5,027
-10% -$213K ﹤0.01% 3186
2021
Q3 		$2.48M Buy
52,866
+6,207
+13% +$333K ﹤0.01% 2715
2021
Q2 		$2.85M Buy
46,659
+22,185
+91% +$1.27M ﹤0.01% 2689
2021
Q1 		$1.51M Sell
24,474
-12,058
-33% -$789K ﹤0.01% 2890
2020
Q4 		$2.6M Buy
36,532
+30,631
+519% +$1.48M ﹤0.01% 2510
2020
Q3 		$222K Buy
+5,901
New +$186K ﹤0.01% 3427
2020
Q2 		– Sell
-9,792
Closed -$284K – 3643
2020
Q1 		$284K Buy
9,792
+2,941
+43% +$91.2K ﹤0.01% 3285
2019
Q4 		$240K Buy
+6,851
New +$190K ﹤0.01% 3493

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Invesco's BBIO Position: Q2 2026 in Review

Invesco reduced its BridgeBio Pharma (BBIO) stake by 19% in Q2 2026, selling an estimated $62.5M and leaving 3,700,934 shares worth $276M. The position accounts for 0.02% of the portfolio, ranked #619.

Invesco first reported a position in BBIO in Q4 2019 and has held it in 26 quarters since. The position peaked at $370M in Q4 2025. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Invesco held 3,700,934 shares of BridgeBio Pharma worth $276M as of Q2 2026.
  • Invesco sold 891,880 BridgeBio Pharma shares in Q2 2026, an estimated $62.5M.
  • BridgeBio Pharma made up 0.02% of Invesco's portfolio in Q2 2026, its #619 holding.
  • Invesco first reported a position in BridgeBio Pharma in Q4 2019 and has held it in 26 quarters since.
  • Invesco's BridgeBio Pharma position peaked at $370M in Q4 2025.
  • 475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.